General Information
Revision date
2019-10-22
Product name
Norgestimate and Ethinyl Estradiol Tablets USP 0.25 mg and 0.035 mg
CAS No.
35189-28-7
Manufacturer Name
Lupin Limited
Icons in SDS
Company Information
company name
Lupin Limited
Section 2
SECTION 2: Hazards identification
Health Do not prescribe norgestimate and ethinyl estradiol tablets to women who are known to have the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: o Smoke, if over age 35 o Have deep vein thrombosis or pulmonary embolism, now or in the past o Have inherited or acquired hypercoagulopathies o Have cerebrovascular disease o Have coronary artery disease o Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) o Have uncontrolled hypertension o Have diabetes mellitus with vascular disease o Have headaches with focal neurological symptoms or migraine headaches with aura Women over age 35 with any migraine headaches Liver tumors, benign or malignant, or liver disease Undiagnosed abnormal uterine bleeding Pregnancy, because there is no reason to use COCs during pregnancy Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations
Environmental hazards
No information is available about the potential of this product to produce adverse environmental effects.